Mavacamten for treating obstructive hypertrophic cardiomyopathy

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg capsules for treating obstructive hypertrophic cardiomyopathy, in line with the following criteria:

  • Patients must have New York Heart Association (NYHA) class II to III, peak left ventricular outflow tract (LVOT) gradient ≥50 mmHg (at rest or with provocation), and left ventricular ejection fraction ≥55%; and

  • Patients must have had an inadequate response to prior trials of (i) a beta-blocker (BB) and (ii) a non-dihydropyridine calcium channel blocker (CCB), unless these are contraindicated or not tolerated; and

  • Mavacamten must be used as an add-on to optimised standard care including a BB and/or a CCB, unless contraindicated or not tolerated.

For continuation of treatment, the patient must have demonstrated a response after receiving the optimal dose of mavacamten for at least 4-6 months, defined as an improvement in at least one of the following: (i) NYHA class, (ii) exercise capacity, or (iii) peak LVOT gradient.

Funding status

Mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

Mavacamten for treating obstructive hypertrophic cardiomyopathy (Published 4 Jun 2025)

PES_Mavacamten for treating obstructive hypertrophic cardiomyopathy (Published 4 Jun 2025)